LIGAND PHARMACEUTICALS INC

LGNYZSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 886163

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$131.3M	$196.2M	$241.5M	$163.6M	$120.3M
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$24.5M	$36.1M	$32.1M	$40.5M	$55.9M
Operating Income (Loss)	$11.9M	$3.0M	$103.9M	$37.5M	$807.1M
Interest Expense	—	—	$19.6M	$27.4M	$35.7M
Nonoperating Income (Expense)	$51.7M	$33.0M	-$31.6M	-$36.2M	-$10.4M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$63.7M	$36.0M	$72.2M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$941.8M	$787.2M	$762.7M	$1.3B	$1.4B
Assets, Current	$331.6M	$237.4M	$263.6M	$464.8M	$500.6M
Cash and Cash Equivalents, at Carrying Value	$72.3M	$23.0M	$45.0M	$19.5M	$47.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$38.4M	$32.9M	$30.4M	$85.5M	$56.8M
Inventory, Net	$14.1M	$24.0M	$13.3M	$27.3M	$26.5M
Liabilities	$111.3M	$86.3M	$165.2M	$476.4M	$652.8M
Liabilities, Current	$37.1M	$16.8M	$98.8M	$41.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$49.6M	$137.8M	$78.8M	$54.6M	-$29.3M
Net Cash Provided by (Used in) Investing Activities	-$11.7M	$163.6M	$30.5M	$231.6M	$466.9M
Net Cash Provided by (Used in) Financing Activities	-$59.9M	-$276.0M	-$137.8M	-$310.5M	-$485.2M
Payments to Acquire Property, Plant, and Equipment	$3.5M	$17.9M	$8.8M	$4.5M	$2.6M
Payments for Repurchase of Common Stock	$0.00	—	—	$78.0M	$453.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)